Aug 2026· Analytical Chemistry· Vol 98 34, pp.
24843-24854
· 0 citations· 37 references
Medicine
TL;DR
A sample-aware diaPASEF method optimization strategy for a timsTOF platform that demonstrates the most substantial impact on low-abundance proteins and provides an opportunity for a more precise and comprehensive analysis of the biological functions of biomarkers.
Abstract
Recent instrumental and computational innovations in mass-spectrometry-based proteomics offer new promise in biomarker discovery, thanks to unprecedented proteome coverage and depth. Data-independent acquisition (DIA) methods are very promising in this context as they allow improved proteome coverage, reduced missing value rates, and enhanced quantification precision. However, DIA methods also suffer from their own challenges, such as increased data complexity, cycle times, and background noise. In this work, we propose a sample-aware diaPASEF method optimization strategy for a timsTOF platform. Thorough method optimizations have first been conducted on standard HeLa lysates. Then, a ground-truth calibrated sample series, consisting of a range of UPS amounts spiked into a complex Arabidopsis background, was used to mimic differential analyses under controlled conditions. These benchmark experiments demonstrate clear benefits of using narrowPASEF for differential protein discovery. Finally, our strategy was applied to real use case biological samples to conduct a differential analysis of purified mouse astrocyte cells across two different conditions. narrowPASEF improved the proteome depth by 13%, considering proteins quantified with a coefficient of variation (CV) of <20%, and led to a 68% (435 vs 729) increase in differentially expressed proteins. These results provide an opportunity for a more precise and comprehensive analysis of the biological functions of biomarkers, offering a more profound understanding of the disease mechanisms. The benefits of our sample-aware narrowPASEF strategy demonstrated the most substantial impact on low-abundance proteins. Overall, these results show promise for more valuable and robust biomarker discoveries in the future.
Chemoproteomics aims to achieve precise and comprehensive quantification of protein-small molecule interactions, yet methodological comparisons across quantitative proteomics workflows remain scarce. Here, we systematically benchmark tandem mass tag data-dependent acquisition (TMT-DDA) on Orbitrap Exploris/Eclipse inst...
Ursula M. Glocker, Michael Steidel, Henrik M. Hammarén et al.· Proteomics· 1 citation
A scalable workflow for the deep proteomic analysis of low- to ultralow-input samples by systematically optimizing a widely adopted Orbitrap and UHPLC platform to maximize sensitivity, precision, and throughput is developed.
Dongyoon Shin, Sumin Lee, S. Yang et al.· Analytical Chemistry· 0 citations
Advances in mass spectrometry (MS) instrumentation and protein extraction technologies are reshaping proteomics; however, whether improved analytical performance alters the biological information accessible from different sample preparation strategies remains unclear. Here, we performed a cross-platform evaluation usin...
Drosos Katsavelis, M. V. D. van der Hart, J. Wolters et al.· Journal of Proteome Research· 0 citations
ProteoScopeR is an R package and Shiny application that connects decisions in a traceable workflow and complements downstream exploration in xOmicsShiny and describes sensitivity to analytical choices rather than identify a universally superior method.
A protein corona-based secretome profiling strategy is developed and incorporated into a multiomics analytical framework, enabling secretome profiling in a model that better preserves tumor heterogeneity and microenvironmental context and establishes a robust and scalable strategy for incorporating the secretome into m...
Cai-Wei Hu, Jia-Liang Zhao, Qian Li et al.· Analytical Chemistry· 0 citations
High-throughput proteomics now spans several technologies that differ in biological breadth, precision, specificity, sensitivity, cost, and method(s) of quantification; however, investigators currently lack an evidence-based framework to select or combine platforms. Here, we present the Atlas of Proteomic Technologies...
Christopher D. Whelan, K. Smith-Byrne· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.